Neurimmune Holding AG
http://www.neurimmune.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neurimmune Holding AG
AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win
AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.
Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data
The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.
AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance
The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.
Aduhelm Approval Is Breakthrough For Neurimmune, Company Which Discovered It
The co-founder of the Swiss company which discovered aducanumab looks back over its 20 year wait for approval, and ahead to future growth plans.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice